

## NORD Press Release

Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD) today issued the following statement of support for provisions related to rare diseases in the Food and Drug Administration's newly-released "PDUFA V" document:

"The FDA's newly-released PDUFA V document entitled 'Advancing Development of Drugs for Rare Diseases' contains elements for which NORD has been advocating for some time. We are especially delighted that this document calls for an additional five staff members in the Rare Disease Program in the FDA Center for Drug Evaluation and Research (CDER), and the creation of a liaison within the Biologics Center. The document reflects a clear recognition that drugs for rare diseases warrant special consideration and special staff training. On behalf of the patient community, I want to thank the FDA for working with us on these advances in the regulatory framework, and we look forward to continued collaboration."

-----

The [draft document](#) has been posted on the FDA website. It outlines the current status of the documentation for the reauthorization of the Prescription Drug User Fee Act.

Established in 1983, NORD is a nonprofit organization representing the nearly 30 million Americans who have rare diseases. It provides advocacy, education, research, and patient assistance programs on behalf of all Americans affected by rare diseases.